The consensus on Rocket Lab USA (RKLB) is that it's one of the market's strongest growth stories. A nearly 250% gain in a single year, moving from around $21 per share to more than $73, is rooted in substantial operational progress. But with the latest rally, investors face the reality that the company is still reliant on a product that hasn't yet launched.
Backlog Surges and Record-Breaking Missions Drive Enthusiasm
Rocket Lab delivered record revenue of $602 million in the most recent year, a 38% year-over-year increase. Its backlog jumped 73% to almost $1.9 billion, providing strong visibility. Rocket Lab flew 21 missions with a 100% success rate last year, landing a $816 million contract from the Space Development Agency. Notably, its space systems segment now makes up roughly 67% of total revenue, shifting Rocket Lab's focus beyond launches alone.
Stocks365 Take: Multiple Hinges on Neutron Execution
Despite these achievements, Rocket Lab trades at about 66 times sales. With the company losing nearly $200 million on $602 million in revenue, the stock price implies an expectation that future growth—largely from the upcoming Neutron rocket—will materialize in full. Neutron promises a price advantage of about $15 million less per launch compared to SpaceX's Falcon 9. However, as the source notes, Neutron is yet to fly and its reliability is unproven. Without its success, the current premium may be difficult to justify.
History Warns: SPAC Analogies and the Importance of Delivery
Investors have seen similar stories before, particularly in the 2021 SPAC boom, where revenue multiples soared on the promise of new rockets that struggled to launch and deliver. Unlike some failed peers, Rocket Lab already delivers operational results with a functioning product and diversified revenue. Still, as the source highlights, when high-multiple stocks price in an unproven product, outcomes diverge sharply depending on execution.
What to Watch: Neutron Launch Timeline Remains Critical
The next major catalyst is Neutron's development and first flight. As the company executes its backlog—almost $1.9 billion in commitments—investors should remember that not all backlog becomes revenue, especially if critical milestones aren't met. For now, expectations are high, and tail risk remains if Neutron faces further delays or setbacks. This dynamic—not just operational reporting—defines the risk/reward for Rocket Lab holders through the next quarter and beyond.
